Haystack MRD Test

Create better outcomes with better MRD testing

Unmatched ctDNA detection sensitivity and specificity for confident MRD testing. Arriving Soon.

For Clinicians

Haystack MRD™ is the most sensitive minimal residual disease (MRD) test available, so you can have the best information to make treatment management decisions that lead to favorable patient outcomes. Our unmatched test performance delivers the best clinical information when answering patients' three most pressing post-surgery questions: 

01
Do I need more treatment?
02
Is my adjuvant treatment working?
03
How will I know if my cancer comes back?

by the numbers

Why test for ctDNA?

Circulating tumor DNA (ctDNA) detection is a non-invasive method to assess tumor burden with a blood sample. Recent data also correlate ctDNA levels in post-surgical cancer patients with recurrence-free survival (RFS) and risk of recurrence.

0 %
ctDNA(-) patient
3-yr RFS*
20 %
ctDNA(+) patient
3-yr RFS*
0 X
ctDNA(+) patients*
more likely to recur

*Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92. doi:10.1126/scitranslmed.aaf6219

Quick View

Haystack MRD Test

Haystack MRD™ is a tumor-informed, liquid biopsy test that begins with tumor whole-exome sequencing (WES) to identify patient-specific somatic mutations. A personalized MRD test is then developed to detect ctDNA, which indicates the presence of residual, recurrent, or resistant disease.

Click to enlarge

Haystack MRD

MRD-based treatment management

Haystack MRD is purpose-built for ultra-sensitive ctDNA detection in patients with solid tumors and can be used to detect residual disease to guide adjuvant therapy, to monitor treatment response, and for recurrence surveillance.

Click to enlarge

HS-grid-items (3)

Proven MRD test superiority

This unique ability delivers unmatched sensitivity, with successful detection down to 1 part per million (PPM; or, 0.0001% tumor fraction), which translates to fewer false-negatives to ensure patients who need treatment receive it, and for greater lead time between molecular and clinical recurrence.

HS-grid-items (1)
floating border 1

News & Events

The Latest

Find out what's happening at Haystack Oncology and stay up-to-date with industry news.